FindTrial
Sign In

A Randomized, Double-Blind, Phase I/II Study of CT-P13 Compared with Remicade in Patients with Rheumatoid Arthritis

A Randomized, Double-Blind, Phase I/II Study of CT-P13 Compared with Remicade in Patients with Rheumatoid Arthritis

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221580
Enrollment
Unknown
Registered
2011-09-13
Start date
2011-09-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

investigational material(s) Generic name etc : CT-P13 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigation

Sponsors

Nippon Kayaku Co., Ltd.
Lead Sponsor
Celltrion, Group
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient was diagnosed RA according to the revised 1987 ACR classification criteria for at least 1 year prior to Screening

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026